Suppr超能文献

抗凝强度对非瓣膜性心房颤动患者止血标志物的影响。

Effects of anticoagulation intensity on hemostatic markers in patients with non-valvular atrial fibrillation.

作者信息

Nozawa Takashi, Inoue Hiroshi, Iwasa Atsushi, Okumura Ken, Jong-dae Lee, Shimizu Akihiko, Hayano Motonobu, Yano Katsusuke

机构信息

Second Department of Internal Medicine, Toyama Medical & Pharmaceutical University, Sugitani, Japan.

出版信息

Circ J. 2004 Jan;68(1):29-34. doi: 10.1253/circj.68.29.

Abstract

BACKGROUND

Elevation of hemostatic markers may account for the increased risk of ischemic stroke in patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to determine the effects of anticoagulation intensity on hemostatic markers in patients with NVAF.

METHODS AND RESULTS

In 509 patients with NVAF, comprising 263 patients treated with warfarin and 246 patients without warfarin, the hemostatic markers of prothrombin fragment F1.2 (F1.2), fibrin D-dimer, platelet factor 4 (PF4), and beta-thromboglobulin were determined and compared with those in 111 patients with sinus rhythm. F1.2 was inversely related with anticoagulation intensity and D-dimer increased with age. All hemostatic markers, except F1.2, were greater in patients with NVAF than in patients with sinus rhythm. F1.2 and D-dimer were significantly lower in patients with international normalized ratio (INR) > or =1.5 than in NVAF patients without warfarin and were not different between NVAF patients with INR of 1.5-1.9 and with INR > or =2.0.

CONCLUSIONS

Low intensity of anticoagulation (INR 1.5-1.9) suppresses the elevated concentration of F1.2 and D-dimer in patients with NVAF, and might be favorable in Japanese patients with NVAF in view of the balance between prevention of thromboembolism and the adverse effect by warfarin (ie, bleeding).

摘要

背景

止血标志物升高可能是导致非瓣膜性心房颤动(NVAF)患者缺血性卒中风险增加的原因。本研究旨在确定抗凝强度对NVAF患者止血标志物的影响。

方法与结果

在509例NVAF患者中,263例接受华法林治疗,246例未接受华法林治疗,测定其凝血酶原片段F1.2(F1.2)、纤维蛋白D-二聚体、血小板因子4(PF4)和β-血小板球蛋白等止血标志物,并与111例窦性心律患者的这些指标进行比较。F1.2与抗凝强度呈负相关,D-二聚体随年龄增加而升高。除F1.2外,NVAF患者的所有止血标志物均高于窦性心律患者。国际标准化比值(INR)≥1.5的患者F1.2和D-二聚体显著低于未接受华法林治疗的NVAF患者,INR为1.5 - 1.9的NVAF患者与INR≥2.0的NVAF患者之间无差异。

结论

低强度抗凝(INR 1.5 - 1.9)可抑制NVAF患者F1.2和D-二聚体浓度升高,从预防血栓栓塞与华法林不良反应(即出血)的平衡角度来看,这可能对日本NVAF患者有利。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验